: T-cell receptor binding to MHC-peptide complexes with different biological activities will be investigated to understand the relationship between TCR binding and activation, and thymocyte development. This 3roposal focuses on MHCp interaction with membrane-bound TCR. TCR-MHCp binding kinetics will be measured in relation to positive and negative selection, using tetramer binding studies. BIAcore analysis of the interaction between soluble TCR and MHCp will identify differences in the relative binding interactions when the TCR is isolated versus in the membrane in complex with CD3, and in the presence of co-receptors. The relationship between TCR binding and positive/negative selection will be investigated using natural positive selecting ligands and a series of ligands that span the border between 3ositive and negative selection. This will allow us to see how the TCR binding strength influences thymocyte selection. We will determine binding for MHCp ligands of different biological activity in the 3resence and absence of CD8. MHCp interaction kinetics with membrane-bound TCR and co-receptor will be studied using T cell membranes bound to BIAcore sensor chips, to measure the on and off rates for MHCp binding to TCR in the presence of the complete TCR:CD3 complex. The influence of CD8aa and ab on MHC class I:TCR binding and dissociation will be measured. Membranes from immature thymocytes will be used to understand how non-cognate CD8:MHCp interactions synergize with binding of TCR to MHCp, and the effect of sialylation on these interactions. Effects of altering lipid raft composition on TCR binding kinetics will be investigated. TCR dimerization and co-receptor interactions at the cell surface will be investigated using MHCp molecules and antibodies as cross-linking agents. Different strength ligands will be compared in order to determine how affinity and kinetics relates to the interaction between TCR and co-receptor. The potential dissociation of the TCR:CD3 complex after T-cell activation will be investigated using these techniques. TCR dimerization will be investigated in solution, using biophysical methods including FRET, analytical ultracentrifugation and BIAcore.

National Institute of Health (NIH)
National Institute of General Medical Sciences (NIGMS)
Research Project (R01)
Project #
Application #
Study Section
Immunobiology Study Section (IMB)
Program Officer
Marino, Pamela
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Scripps Research Institute
La Jolla
United States
Zip Code
Yachi, Pia P; Ampudia, Jeanette; Zal, Tomasz et al. (2006) Altered peptide ligands induce delayed CD8-T cell receptor interaction--a role for CD8 in distinguishing antigen quality. Immunity 25:203-11
Yachi, Pia P; Ampudia, Jeanette; Gascoigne, Nicholas R J et al. (2005) Nonstimulatory peptides contribute to antigen-induced CD8-T cell receptor interaction at the immunological synapse. Nat Immunol 6:785-92
Holmberg, Kaisa; Mariathasan, Sanjeev; Ohteki, Toshiaki et al. (2003) TCR binding kinetics measured with MHC class I tetramers reveal a positive selecting peptide with relatively high affinity for TCR. J Immunol 171:2427-34
Sim, Bee-Cheng; Holmberg, Kaisa; Sidobre, Stephane et al. (2003) Surprisingly minor influence of TRAV11 (Valpha14) polymorphism on NK T-receptor mCD1/alpha-galactosylceramide binding kinetics. Immunogenetics 54:874-83
Alam, S Munir; Gascoigne, Nicholas R J (2003) Binding kinetics of superantigen with TCR and MHC class II. Methods Mol Biol 214:65-85
Sidobre, Stephane; Naidenko, Olga V; Sim, Bee-Cheng et al. (2002) The V alpha 14 NKT cell TCR exhibits high-affinity binding to a glycolipid/CD1d complex. J Immunol 169:1340-8
Zal, Tomasz; Zal, M Anna; Gascoigne, Nicholas R J (2002) Inhibition of T cell receptor-coreceptor interactions by antagonist ligands visualized by live FRET imaging of the T-hybridoma immunological synapse. Immunity 16:521-34
Alam, S M; Davies, G M; Lin, C M et al. (1999) Qualitative and quantitative differences in T cell receptor binding of agonist and antagonist ligands. Immunity 10:227-37